PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of envhperEnvironmental Health PerspectivesBrowse ArticlesAbout EHPGeneral InformationAuthorsMediaProgramsPartnerships
 
Environ Health Perspect. 1997 September; 105(9): 928–939.
PMCID: PMC1470371
Research Article

Renal effects of environmental and occupational lead exposure.

Abstract

Environmental and industrial lead exposures continue to pose major public health problems in children and in adults. Acute exposure to high concentrations of lead can result in proximal tubular damage with characteristic histologic features and manifested by glycosuria and aminoaciduria. Chronic occupational exposure to lead, or consumption of illicit alcohol adulterated with lead, has also been linked to a high incidence of renal dysfunction, which is characterized by glomerular and tubulointerstitial changes resulting in chronic renal failure, hypertension, hyperuricemia, and gout. A high incidence of nephropathy was reported during the early part of this century from Queensland, Australia, in persons with a history of childhood lead poisoning. No such sequela has been found in studies of three cohorts of lead-poisoned children from the United States. Studies in individuals with low-level lead exposure have shown a correlation between blood lead levels and serum creatinine or creatinine clearance. Chronic low-level exposure to lead is also associated with increased urinary excretion of low molecular weight proteins and lysosomal enzymes. The relationship between renal dysfunction detected by these sensitive tests and the future development of chronic renal disease remains uncertain. Epidemiologic studies have shown an association between blood lead levels and blood pressure, and hypertension is a cardinal feature of lead nephropathy. Evidence for increased body lead burden is a prerequisite for the diagnosis of lead nephropathy. Blood lead levels are a poor indicator of body lead burden and reflect recent exposure. The EDTA lead mobilization test has been used extensively in the past to assess body lead burden. It is now replaced by the less invasive in vivo X-ray fluorescence for determination of bone lead content.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (4.7M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Images in this article

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Bernard BP, Becker CE. Environmental lead exposure and the kidney. J Toxicol Clin Toxicol. 1988;26(1-2):1–34. [PubMed]
  • Rosen JF. Adverse health effects of lead at low exposure levels: trends in the management of childhood lead poisoning. Toxicology. 1995 Mar 31;97(1-3):11–17. [PubMed]
  • Needleman HL, Gatsonis CA. Low-level lead exposure and the IQ of children. A meta-analysis of modern studies. JAMA. 1990 Feb 2;263(5):673–678. [PubMed]
  • Goyer RA. Lead toxicity: current concerns. Environ Health Perspect. 1993 Apr;100:177–187. [PMC free article] [PubMed]
  • Pirkle JL, Brody DJ, Gunter EW, Kramer RA, Paschal DC, Flegal KM, Matte TD. The decline in blood lead levels in the United States. The National Health and Nutrition Examination Surveys (NHANES) JAMA. 1994 Jul 27;272(4):284–291. [PubMed]
  • Mushak P. Defining lead as the premiere environmental health issue for children in America: criteria and their quantitative application. Environ Res. 1992 Dec;59(2):281–309. [PubMed]
  • Wedeen RP. The role of lead in renal failure. Clin Exp Dial Apheresis. 1982;6(2-3):113–146. [PubMed]
  • Batuman V. Lead nephropathy, gout, and hypertension. Am J Med Sci. 1993 Apr;305(4):241–247. [PubMed]
  • HENDERSON DA. A follow-up of cases of plumbism in children. Australas Ann Med. 1954 Aug;3(3):219–224. [PubMed]
  • Bennett WM. Lead nephropathy. Kidney Int. 1985 Aug;28(2):212–220. [PubMed]
  • Morgan JM, Hartley MW, Miller RE. Nephropathy in chronic lead poisoning. Arch Intern Med. 1966 Jul;118(1):17–29. [PubMed]
  • Wedeen RP, Maesaka JK, Weiner B, Lipat GA, Lyons MM, Vitale LF, Joselow MM. Occupational lead nephropathy. Am J Med. 1975 Nov;59(5):630–641. [PubMed]
  • Silbergeld EK. Implications of new data on lead toxicity for managing and preventing exposure. Environ Health Perspect. 1990 Nov;89:49–54. [PMC free article] [PubMed]
  • Elhelu MA, Caldwell DT, Hirpassa WD. Lead in inner-city soil and its possible contribution to children's blood lead. Arch Environ Health. 1995 Mar-Apr;50(2):165–169. [PubMed]
  • Bernard AM, Vyskocil A, Roels H, Kriz J, Kodl M, Lauwerys R. Renal effects in children living in the vicinity of a lead smelter. Environ Res. 1995 Feb;68(2):91–95. [PubMed]
  • Campbell BC, Beattie AD, Moore MR, Goldberg A, Reid AG. Renal insufficiency associated with excessive lead exposure. Br Med J. 1977 Feb 19;1(6059):482–485. [PMC free article] [PubMed]
  • Goyer RA, Mahaffey KR. Susceptibility to lead toxicity. Environ Health Perspect. 1972 Oct;2:73–80. [PMC free article] [PubMed]
  • Pollock CA, Ibels LS. Lead nephropathy--a preventable cause of renal failure. Int J Artif Organs. 1988 Mar;11(2):75–78. [PubMed]
  • Pollock CA, Ibels LS. Lead intoxication in paint removal workers on the Sydney Harbour Bridge. Med J Aust. 1986 Dec 1;145(11-12):635–639. [PubMed]
  • Ritz E, Wiecek A, Stoeppler M. Lead Nephropathy. Contrib Nephrol. 1987;55:185–191. [PubMed]
  • Goyer RA. The renal tubule in lead poisoning. I. mMitochondrial swelling and aminoacidura. Lab Invest. 1968 Jul;19(1):71–77. [PubMed]
  • Goyer RA. Mechanisms of lead and cadmium nephrotoxicity. Toxicol Lett. 1989 Mar;46(1-3):153–162. [PubMed]
  • Landrigan PJ. Toxicity of lead at low dose. Br J Ind Med. 1989 Sep;46(9):593–596. [PMC free article] [PubMed]
  • Nolan CV, Shaikh ZA. Lead nephrotoxicity and associated disorders: biochemical mechanisms. Toxicology. 1992;73(2):127–146. [PubMed]
  • Moore JF, Goyer RA, Wilson M. Lead-induced inclusion bodies. Solubility, amino acid content, and relationship to residual acidic nuclear proteins. Lab Invest. 1973 Nov;29(5):488–494. [PubMed]
  • Goyer RA, May P, Cates MM, Krigman MR. Lead and protein content of isolated intranuclear inclusion bodies from kidneys of lead-poisoned rats. Lab Invest. 1970 Mar;22(3):245–251. [PubMed]
  • Vyskocil A, Pancl J, Tusl M, Ettlerova E, Semecky V, Kasparová L, Lauwerys R, Bernard A. Dose-related proximal tubular dysfunction in male rats chronically exposed to lead. J Appl Toxicol. 1989 Dec;9(6):395–399. [PubMed]
  • WILSON VK, THOMSON ML, DENT CE. Amino-aciduria in lead poisoning; a case in childhood. Lancet. 1953 Jul 11;265(6776):66–68. [PubMed]
  • Goyer RA, Leonard DL, Bream PR, Irons TG. Aminoaciduria in experimental lead poisoning. Proc Soc Exp Biol Med. 1970 Dec;135(3):767–771. [PubMed]
  • CHISOLM JJ, Jr, HARRISON HC, EBERLEIN WR, HARRISON HE. Amino-aciduria, hypophosphatemia, and rickets in lead poisoning; study of a case. AMA Am J Dis Child. 1955 Feb;89(2):159–168. [PubMed]
  • CHISOLM JJ., Jr Aminoaciduria as a manifestation of renal tubular injury in lead intoxication and a comparison with patterns of aminoaciduria seen in other diseases. J Pediatr. 1962 Jan;60:1–17. [PubMed]
  • Hammond PB. Exposure of humans to lead. Annu Rev Pharmacol Toxicol. 1977;17:197–214. [PubMed]
  • Waldegger S, Schmidt F, Herzer T, Gulbins E, Schuster A, Biber J, Markovich D, Murer H, Busch AE, Lang F. Heavy metal mediated inhibition of rBAT-induced amino acid transport. Kidney Int. 1995 Jun;47(6):1677–1681. [PubMed]
  • Rosen JF, Chesney RW, Hamstra A, DeLuca HF, Mahaffey KR. Reduction in 1,25-dihydroxyvitamin D in children with increased lead absorption. N Engl J Med. 1980 May 15;302(20):1128–1131. [PubMed]
  • Aviv A, John E, Bernstein J, Goldsmith DI, Spitzer A. Lead intoxication during development: its late effects on kidney function and blood pressure. Kidney Int. 1980 Apr;17(4):430–437. [PubMed]
  • Khalil-Manesh F, Gonick HC, Cohen AH, Alinovi R, Bergamaschi E, Mutti A, Rosen VJ. Experimental model of lead nephropathy. I. Continuous high-dose lead administration. Kidney Int. 1992 May;41(5):1192–1203. [PubMed]
  • Khalil-Manesh F, Gonick HC, Cohen A, Bergamaschi E, Mutti A. Experimental model of lead nephropathy. II. Effect of removal from lead exposure and chelation treatment with dimercaptosuccinic acid (DMSA). Environ Res. 1992 Jun;58(1):35–54. [PubMed]
  • Emmerson BT. Chronic lead nephropathy. Kidney Int. 1973 Jul;4(1):1–5. [PubMed]
  • Nuyts GD, Daelemans RA, Jorens PG, Elseviers MM, Van de Vyver FL, De Broe ME. Does lead play a role in the development of chronic renal disease? Nephrol Dial Transplant. 1991;6(5):307–315. [PubMed]
  • Chia KS, Mutti A, Alinovi R, Jeyaratnam J, Tan C, Ong CN, Lee E. Urinary excretion of tubular brush-border antigens among lead exposed workers. Ann Acad Med Singapore. 1994 Sep;23(5):655–659. [PubMed]
  • DANILOVIC V. Chronic nephritis due to ingestion of lead-contaminated flour. Br Med J. 1958 Jan 4;1(5061):27–28. [PMC free article] [PubMed]
  • Baker EL, Jr, Landrigan PJ, Barbour AG, Cox DH, Folland DS, Ligo RN, Throckmorton J. Occupational lead poisoning in the United States: clinical and biochemical findings related to blood lead levels. Br J Ind Med. 1979 Nov;36(4):314–322. [PMC free article] [PubMed]
  • Pinto de Almeida AR, Carvalho FM, Spinola AG, Rocha H. Renal dysfunction in Brazilian lead workers. Am J Nephrol. 1987;7(6):455–458. [PubMed]
  • Lilis R, Fischbein A, Valciukas JA, Blumberg W, Selikoff IJ. Kidney function and lead: relationships in several occupational groups with different levels of exposure. Am J Ind Med. 1980;1(3-4):405–412. [PubMed]
  • Staessen JA, Lauwerys RR, Buchet JP, Bulpitt CJ, Rondia D, Vanrenterghem Y, Amery A. Impairment of renal function with increasing blood lead concentrations in the general population. The Cadmibel Study Group. N Engl J Med. 1992 Jul 16;327(3):151–156. [PubMed]
  • Staessen J, Yeoman WB, Fletcher AE, Markowe HL, Marmot MG, Rose G, Semmence A, Shipley MJ, Bulpitt CJ. Blood lead concentration, renal function, and blood pressure in London civil servants. Br J Ind Med. 1990 Jul;47(7):442–447. [PMC free article] [PubMed]
  • Kim R, Rotnitsky A, Sparrow D, Weiss S, Wager C, Hu H. A longitudinal study of low-level lead exposure and impairment of renal function. The Normative Aging Study. JAMA. 1996 Apr 17;275(15):1177–1181. [PubMed]
  • Hong CD, Hanenson IB, Lerner S, Hammond PB, Pesce AJ, Pollak VE. Occupational exposure to lead: effects on renal function. Kidney Int. 1980 Oct;18(4):489–494. [PubMed]
  • Cooper WC, Gaffey WR. Mortality of lead workers. J Occup Med. 1975 Feb;17(2):100–107. [PubMed]
  • Malcolm D, Barnett HA. A mortality study of lead workers 1925-76. Br J Ind Med. 1982 Nov;39(4):404–410. [PMC free article] [PubMed]
  • Selevan SG, Landrigan PJ, Stern FB, Jones JH. Mortality of lead smelter workers. Am J Epidemiol. 1985 Oct;122(4):673–683. [PubMed]
  • Davies JM. Long term mortality study of chromate pigment workers who suffered lead poisoning. Br J Ind Med. 1984 May;41(2):170–178. [PMC free article] [PubMed]
  • Verschoor M, Wibowo A, Herber R, van Hemmen J, Zielhuis R. Influence of occupational low-level lead exposure on renal parameters. Am J Ind Med. 1987;12(4):341–351. [PubMed]
  • Gerhardsson L, Chettle DR, Englyst V, Nordberg GF, Nyhlin H, Scott MC, Todd AC, Vesterberg O. Kidney effects in long term exposed lead smelter workers. Br J Ind Med. 1992 Mar;49(3):186–192. [PMC free article] [PubMed]
  • Greenberg A, Parkinson DK, Fetterolf DE, Puschett JB, Ellis KJ, Wielopolski L, Vaswani AN, Cohn SH, Landrigan PJ. Effects of elevated lead and cadmium burdens on renal function and calcium metabolism. Arch Environ Health. 1986 Mar-Apr;41(2):69–76. [PubMed]
  • Chia KS, Jeyaratnam J, Tan C, Ong HY, Ong CN, Lee E. Glomerular function of lead-exposed workers. Toxicol Lett. 1995 May;77(1-3):319–328. [PubMed]
  • Buchet JP, Roels H, Bernard A, Lauwerys R. Assessment of renal function of workers exposed to inorganic lead, calcium or mercury vapor. J Occup Med. 1980 Nov;22(11):741–750. [PubMed]
  • Omae K, Sakurai H, Higashi T, Muto T, Ichikawa M, Sasaki N. No adverse effects of lead on renal function in lead-exposed workers. Ind Health. 1990;28(2):77–83. [PubMed]
  • Emmerson BT. The renal excretion of urate in chronic lead nephropathy. Australas Ann Med. 1965 Nov;14(4):295–303. [PubMed]
  • Inglis JA, Henderson DA, Emmerson BT. The pathology and pathogenesis of chronic lead nephropathy occurring in Queensland. J Pathol. 1978 Feb;124(2):65–76. [PubMed]
  • HENDERSON DA, INGLIS JA. The lead content of bone in chronic Bright's disease. Australas Ann Med. 1957 May;6(2):145–154. [PubMed]
  • EMMERSON BT. CHRONIC LEAD NEPHROPATHY: THE DIAGNOSTIC USE OF CALCIUM EDTA AND THE ASSOCIATION WITH GOUT. Australas Ann Med. 1963 Nov;12:310–324. [PubMed]
  • TEPPER LB. RENAL FUNCTION SUBSEQUENT TO CHILDHOOD PLUMBISM. Arch Environ Health. 1963 Jul;7:76–85. [PubMed]
  • Goyer RA. Lead and the kidney. Curr Top Pathol. 1971;55:147–176. [PubMed]
  • Moel DI, Sachs HK. Renal function 17 to 23 years after chelation therapy for childhood plumbism. Kidney Int. 1992 Nov;42(5):1226–1231. [PubMed]
  • Hu H. A 50-year follow-up of childhood plumbism. Hypertension, renal function, and hemoglobin levels among survivors. Am J Dis Child. 1991 Jun;145(6):681–687. [PubMed]
  • Payton M, Hu H, Sparrow D, Weiss ST. Low-level lead exposure and renal function in the Normative Aging Study. Am J Epidemiol. 1994 Nov 1;140(9):821–829. [PubMed]
  • Verberk MM, Willems TE, Verplanke AJ, De Wolff FA. Environmental lead and renal effects in children. Arch Environ Health. 1996 Jan-Feb;51(1):83–87. [PubMed]
  • McDonald JA, Potter NU. Lead's legacy? Early and late mortality of 454 lead-poisoned children. Arch Environ Health. 1996 Mar-Apr;51(2):116–121. [PubMed]
  • CRUTCHER JC. CLINICAL MANIFESTATIONS AND THERAPY OF ACUTE LEAD INTOXICATION DUE TO THE INGESTION OF ILLICITLY DISTILLED ALCOHOL. Ann Intern Med. 1963 Nov;59:707–715. [PubMed]
  • Wright LF, Saylor RP, Cecere FA. Occult lead intoxication in patients with gout and kidney disease. J Rheumatol. 1984 Aug;11(4):517–520. [PubMed]
  • Yu TF. Lead nephropathy and gout. Am J Kidney Dis. 1983 Mar;2(5):555–558. [PubMed]
  • LUDWIG GD. Saturnine gout; a secondary type of gout. AMA Arch Intern Med. 1957 Nov;100(5):802–812. [PubMed]
  • Reynolds PP, Knapp MJ, Baraf HS, Holmes EW. Moonshine and lead. Relationship to the pathogenesis of hyperuricemia in gout. Arthritis Rheum. 1983 Sep;26(9):1057–1064. [PubMed]
  • Kaliuzhnyi LV, Litvinova SV, Kaliuzhnyi AL, Aristova VV, Gruden' MA, Kozlov A Iu, Torgovanova GV, Fedoseeva OV. Antitela k morfinu v mekhanizmakh morfinnoi rezistentnosti, morfinnoi tolerantnosti i deistviia antagonista. Eksp Klin Farmakol. 1998 Jan-Feb;61(1):21–24. [PubMed]
  • Ball GV, Sorensen LB. Pathogenesis of hyperuricemia in saturinine gout. N Engl J Med. 1969 May 29;280(22):1199–1202. [PubMed]
  • Wedeen RP, D'Haese P, Van de Vyver FL, Verpooten GA, De Broe ME. Lead nephropathy. Am J Kidney Dis. 1986 Nov;8(5):380–383. [PubMed]
  • Craswell PW. Chronic lead nephropathy. Annu Rev Med. 1987;38:169–173. [PubMed]
  • Goyer RA. Lead and the kidney. Curr Top Pathol. 1971;55:147–176. [PubMed]
  • Batuman V, Maesaka JK, Haddad B, Tepper E, Landy E, Wedeen RP. The role of lead in gout nephropathy. N Engl J Med. 1981 Feb 26;304(9):520–523. [PubMed]
  • Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW. Chronic renal failure with gout: a marker of chronic lead poisoning. Kidney Int. 1984 Sep;26(3):319–323. [PubMed]
  • Wedeen R. Lead and the gouty kidney. Am J Kidney Dis. 1983 Mar;2(5):559–563. [PubMed]
  • Batuman V, Landy E, Maesaka JK, Wedeen RP. Contribution of lead to hypertension with renal impairment. N Engl J Med. 1983 Jul 7;309(1):17–21. [PubMed]
  • Pirkle JL, Schwartz J, Landis JR, Harlan WR. The relationship between blood lead levels and blood pressure and its cardiovascular risk implications. Am J Epidemiol. 1985 Feb;121(2):246–258. [PubMed]
  • Hertz-Picciotto I, Croft J. Review of the relation between blood lead and blood pressure. Epidemiol Rev. 1993;15(2):352–373. [PubMed]
  • Hense HW, Filipiak B, Keil U. The association of blood lead and blood pressure in population surveys. Epidemiology. 1993 Mar;4(2):173–179. [PubMed]
  • de Kort WL, Verschoor MA, Wibowo AA, van Hemmen JJ. Occupational exposure to lead and blood pressure: a study in 105 workers. Am J Ind Med. 1987;11(2):145–156. [PubMed]
  • dos Santos AC, Colacciopo S, Dal Bó CM, dos Santos NA. Occupational exposure to lead, kidney function tests, and blood pressure. Am J Ind Med. 1994 Nov;26(5):635–643. [PubMed]
  • Harlan WR, Landis JR, Schmouder RL, Goldstein NG, Harlan LC. Blood lead and blood pressure. Relationship in the adolescent and adult US population. JAMA. 1985 Jan 25;253(4):530–534. [PubMed]
  • Weiss ST, Muñoz A, Stein A, Sparrow D, Speizer FE. The relationship of blood lead to blood pressure in a longitudinal study of working men. Am J Epidemiol. 1986 May;123(5):800–808. [PubMed]
  • Wolf C, Wallnöfer A, Waldhör T, Vutuc C, Meisinger V, Rüdiger HW. Effect of lead on blood pressure in occupationally nonexposed men. Am J Ind Med. 1995 Jun;27(6):897–903. [PubMed]
  • Hu H, Aro A, Payton M, Korrick S, Sparrow D, Weiss ST, Rotnitzky A. The relationship of bone and blood lead to hypertension. The Normative Aging Study. JAMA. 1996 Apr 17;275(15):1171–1176. [PubMed]
  • Schwartz J. Lead, blood pressure, and cardiovascular disease in men. Arch Environ Health. 1995 Jan-Feb;50(1):31–37. [PubMed]
  • Perry HM, Jr, Erlanger MW, Perry EF. Increase in the blood pressure of rats chronically fed low levels of lead. Environ Health Perspect. 1988 Jun;78:107–111. [PMC free article] [PubMed]
  • Victery W. Evidence for effects of chronic lead exposure on blood pressure in experimental animals: an overview. Environ Health Perspect. 1988 Jun;78:71–76. [PMC free article] [PubMed]
  • Morris C, McCarron DA, Bennett WM. Low-level lead exposure, blood pressure, and calcium metabolism. Am J Kidney Dis. 1990 Jun;15(6):568–574. [PubMed]
  • Lilis R, Gavrilescu N, Nestorescu B, Dumitriu C, Roventa A. Nephropathy in chronic lead poisoning. Br J Ind Med. 1968 Jul;25(3):196–202. [PMC free article] [PubMed]
  • Boscolo P, Carmignani M. Neurohumoral blood pressure regulation in lead exposure. Environ Health Perspect. 1988 Jun;78:101–106. [PMC free article] [PubMed]
  • Kopp SJ, Barron JT, Tow JP. Cardiovascular actions of lead and relationship to hypertension: a review. Environ Health Perspect. 1988 Jun;78:91–99. [PMC free article] [PubMed]
  • Skoczyńska A, Juzwa W, Smolik R, Szechiński J, Behal FJ. Response of the cardiovascular system to catecholamines in rats given small doses of lead. Toxicology. 1986 Jun;39(3):275–289. [PubMed]
  • Chai SS, Webb RC. Effects of lead on vascular reactivity. Environ Health Perspect. 1988 Jun;78:85–89. [PMC free article] [PubMed]
  • Fleischer N, Mouw R, Vander AJ. Chronic effects of lead on renin and renal sodium excretion. J Lab Clin Med. 1980 May;95(5):759–770. [PubMed]
  • Campbell BC, Meredith PA, Scott JJ. Lead exposure and changes in the renin-angiotensin-aldosterone system in man. Toxicol Lett. 1985 Apr;25(1):25–32. [PubMed]
  • Vander AJ. Chronic effects of lead on the renin-angiotensin system. Environ Health Perspect. 1988 Jun;78:77–83. [PMC free article] [PubMed]
  • Batuman V, Dreisbach A, Chun E, Naumoff M. Lead increases red cell sodium-lithium countertransport. Am J Kidney Dis. 1989 Sep;14(3):200–203. [PubMed]
  • Cárdenas A, Roels H, Bernard AM, Barbon R, Buchet JP, Lauwerys RR, Roselló J, Ramis I, Mutti A, Franchini I, et al. Markers of early renal changes induced by industrial pollutants. II. Application to workers exposed to lead. Br J Ind Med. 1993 Jan;50(1):28–36. [PMC free article] [PubMed]
  • Barry PS, Mossman DB. Lead concentrations in human tissues. Br J Ind Med. 1970 Oct;27(4):339–351. [PMC free article] [PubMed]
  • Wedeen RP. Use of the CaNa2 EDTA Pb-mobilization test to detect occult lead nephropathy. Uremia Invest. 1985;9(2):127–130. [PubMed]
  • Markowitz ME, Rosen JF. Assessment of lead stores in children: validation of an 8-hour CaNa2EDTA provocative test. J Pediatr. 1984 Mar;104(3):337–341. [PubMed]
  • Emmerson BT. Lead stores in patients with renal insufficiency. Nephron. 1991;58(2):233–234. [PubMed]
  • Weinberger HL, Post EM, Schneider T, Helu B, Friedman J. An analysis of 248 initial mobilization tests performed on an ambulatory basis. Am J Dis Child. 1987 Dec;141(12):1266–1270. [PubMed]
  • Fournier L, Thomas G, Garnier R, Buisine A, Houze P, Pradier F, Dally S. 2,3-Dimercaptosuccinic acid treatment of heavy metal poisoning in humans. Med Toxicol Adverse Drug Exp. 1988 Nov-Dec;3(6):499–504. [PubMed]
  • Mann KV, Travers JD. Succimer, an oral lead chelator. Clin Pharm. 1991 Dec;10(12):914–922. [PubMed]
  • Ahlgren L, Mattsson S. An X-ray fluorescence technique for in vivo determination of lead concentration in a bone matrix. Phys Med Biol. 1979 Jan;24(1):136–145. [PubMed]
  • Craswell PW, Price J, Boyle PD, Heazlewood VJ, Baddeley H, Lloyd HM, Thomas BJ, Thomas BW, Williams GM. Chronic lead nephropathy in Queensland: alternative methods of diagnosis. Aust N Z J Med. 1986 Feb;16(1):11–19. [PubMed]
  • Wedeen RP, Ty A, Udasin I, Favata EA, Jones KW. Clinical application of in vivo tibial K-XRF for monitoring lead stores. Arch Environ Health. 1995 Sep-Oct;50(5):355–361. [PubMed]
  • Hu H, Milder FL, Burger DE. X-ray fluorescence measurements of lead burden in subjects with low-level community lead exposure. Arch Environ Health. 1990 Nov-Dec;45(6):335–341. [PubMed]
  • Price J, Grudzinski AW, Craswell PW, Thomas BJ. Repeated bone lead levels in Queensland, Australia--previously a high lead environment. Arch Environ Health. 1992 Jul-Aug;47(4):256–262. [PubMed]
  • Price J, Grudzinski AW, Craswell PW, Thomas BJ. Bone lead measurements in patients with chronic renal disease studied over time. Arch Environ Health. 1992 Sep-Oct;47(5):330–335. [PubMed]
  • Somervaille LJ, Chettle DR, Scott MC. In vivo measurement of lead in bone using x-ray fluorescence. Phys Med Biol. 1985 Sep;30(9):929–943. [PubMed]
  • Landrigan PJ, Todd AC. Direct measurement of lead in bone. A promising biomarker. JAMA. 1994 Jan 19;271(3):239–240. [PubMed]
  • Wedeen RD. In vivo tibial XFR measurement of bone lead. Arch Environ Health. 1990 Mar-Apr;45(2):69–71. [PubMed]
  • Sokas RK, Besarab A, McDiarmid MA, Shapiro IM, Bloch P. Sensitivity of in vivo X-ray fluorescence determination of skeletal lead stores. Arch Environ Health. 1990 Sep-Oct;45(5):268–272. [PubMed]
  • Todd AC, McNeill FE, Fowler BA. In vivo X-ray fluorescence of lead in bone. Environ Res. 1992 Dec;59(2):326–335. [PubMed]
  • Bernard A, Lauwerys R. Epidemiological application of early markers of nephrotoxicity. Toxicol Lett. 1989 Mar;46(1-3):293–306. [PubMed]
  • Konishi Y, Endo G, Kiyota A, Horiguchi S. Fractional clearances of low molecular weight proteins in lead workers. Ind Health. 1994;32(3):119–127. [PubMed]
  • Meyer BR, Fischbein A, Rosenman K, Lerman Y, Drayer DE, Reidenberg MM. Increased urinary enzyme excretion in workers exposed to nephrotoxic chemicals. Am J Med. 1984 Jun;76(6):989–998. [PubMed]
  • Murdiati TB, McSweeney CS, Campbell RS, Stoltz DS. Prevention of hydrolysable tannin toxicity in goats fed Clidemia hirta by calcium hydroxide supplementation. J Appl Toxicol. 1990 Oct;10(5):325–331. [PubMed]
  • Khalil-Manesh F, Gonick HC, Cohen AH. Experimental model of lead nephropathy. III. Continuous low-level lead administration. Arch Environ Health. 1993 Jul-Aug;48(4):271–278. [PubMed]
  • Chia KS, Mutti A, Tan C, Ong HY, Jeyaratnam J, Ong CN, Lee E. Urinary N-acetyl-beta-D-glucosaminidase activity in workers exposed to inorganic lead. Occup Environ Med. 1994 Feb;51(2):125–129. [PMC free article] [PubMed]
  • Kumar BD, Krishnaswamy K. Detection of occupational lead nephropathy using early renal markers. J Toxicol Clin Toxicol. 1995;33(4):331–335. [PubMed]
  • Lin JL, Yeh KH, Tseng HC, Chen WY, Lai HH, Lin YC. Urinary N-acetyl-glucosaminidase excretion and environmental lead exposure. Green Cross Health Service Association Study Group. Am J Nephrol. 1993;13(6):442–447. [PubMed]
  • Fels LM, Herbort C, Pergande M, Jung K, Hotter G, Roselló J, Gelpi E, Mutti A, De Broe M, Stolte H. Nephron target sites in chronic exposure to lead. Nephrol Dial Transplant. 1994;9(12):1740–1746. [PubMed]
  • Pergande M, Jung K, Precht S, Fels LM, Herbort C, Stolte H. Changed excretion of urinary proteins and enzymes by chronic exposure to lead. Nephrol Dial Transplant. 1994;9(6):613–618. [PubMed]
  • Chia KS, Jeyaratnam J, Lee J, Tan C, Ong HY, Ong CN, Lee E. Lead-induced nephropathy: relationship between various biological exposure indices and early markers of nephrotoxicity. Am J Ind Med. 1995 Jun;27(6):883–895. [PubMed]
  • RADOSEVIC Z, SARIC M, BERITIC T, KNEZEVIC J. The kidney in lead poisoning. Br J Ind Med. 1961 Jul;18:222–230. [PMC free article] [PubMed]

Articles from Environmental Health Perspectives are provided here courtesy of National Institute of Environmental Health Science